Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links
- PMID: 1991806
- DOI: 10.1210/jcem-72-2-367
Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links
Abstract
Pyridinoline (Pyr) and deoxypyridinoline (D-Pyr) are two cross-links of collagen molecules that are present in the extracellular matrix and released during its degradation. In contrast to the wide distribution of collagen, Pyr is present in bone and cartilage, but not in significant amounts in other connective tissues, and D-Pyr appears to be specific for bone tissue. Therefore, the urinary excretion of Pyr and D-Pyr might be a sensitive marker of bone matrix degradation. Using a specific high pressure liquid chromatography assay we have measured Pyr and D-Pyr cross-links in a 24-h and a fasting urine sample in 60 early postmenopausal women and 19 premenopausal women matched for age. Menopause induced a 62% increase in Fu Pyr (49.8 +/- 18.7 vs. 30.8 +/- 8.0 pmol/mumol creatinine; P less than 0.001) and an 82% increase in Fu D-Pyr (8.2 +/- 3.4 vs. 4.5 +/- 1.4 pmol/mumol creatinine; P less than 0.001). In 20 postmenopausal women on hormone replacement therapy, urinary Pyr and D-Pyr returned to premenopausal levels within 6 months, contrasting with unchanged levels during placebo treatment. The 24-h excretion of Pyr and D-Pyr was significantly lower than the fasting excretion, but was similarly decreased after hormone replacement therapy. Pyr and D-Pyr excretion measured in the same urinary sample were highly correlated (r = 0.85 for fasting and 0.83 for 24-h sampling), but correlations between fasting and 24-h values were weak (D-Pyr, r = 0.30; Pyr, r = 0.29; P less than 0.05 for both). Correlations between urinary cross-links and other markers of bone turnover (Fu hydroxyproline/creatinine and plasma osteocalcin) were significant but low (Pyr vs. osteocalcin, r = 0.29, P less than 0.05; Pyr vs. hydroxyproline, r = 0/.34; P less than 0.01; D-Pyr vs. osteocalcin, r = 0.39; P less than 0.01), except for D-Pyr vs. hydroxyproline (r = 0.24; P = 0.07), suggesting that these markers reflect different events of bone metabolism. Finally, a single measurement of the fasting excretion, but not of the 24-h excretion, of cross-links was significantly correlated (Pyr, r = 0.34; P less than 0.05; D-Pyr, r = -0.46; P less than 0.01), with the subsequent spontaneous rate of bone loss assessed by repeated measurements of the radial bone mineral content in 37 postmenopausal women.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis.J Bone Miner Res. 1991 Jun;6(6):639-44. doi: 10.1002/jbmr.5650060615. J Bone Miner Res. 1991. PMID: 1887826
-
Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia.J Clin Endocrinol Metab. 1992 Mar;74(3):471-5. doi: 10.1210/jcem.74.3.1740478. J Clin Endocrinol Metab. 1992. PMID: 1740478
-
Urinary excretion of pyridinium cross-links in healthy women; the long-term effects of menopause and oestrogen/progesterone therapy.Clin Endocrinol (Oxf). 1994 Jun;40(6):777-82. doi: 10.1111/j.1365-2265.1994.tb02512.x. Clin Endocrinol (Oxf). 1994. PMID: 8033369 Clinical Trial.
-
[Assay of cross-linking molecules of collagen (pyridinolines) in the study of the degradation of bone tissue and articular cartilage].Pathol Biol (Paris). 1993 Dec;41(10):951-61. Pathol Biol (Paris). 1993. PMID: 8159476 Review. French.
-
Biochemical markers of bone turnover.J Bone Miner Res. 1993 Dec;8 Suppl 2:S549-55. doi: 10.1002/jbmr.5650081323. J Bone Miner Res. 1993. PMID: 8122526 Review.
Cited by
-
Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy.Osteoporos Int. 1995;5(4):276-80. doi: 10.1007/BF01774018. Osteoporos Int. 1995. PMID: 7492867 Clinical Trial.
-
Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover.Calcif Tissue Int. 1994 Jan;54(1):26-9. doi: 10.1007/BF00316285. Calcif Tissue Int. 1994. PMID: 8118749 Clinical Trial.
-
New developments in biochemical markers for osteoporosis.Calcif Tissue Int. 1996;59 Suppl 1:S2-9. doi: 10.1007/s002239900168. Calcif Tissue Int. 1996. PMID: 8974724 Review.
-
The effect of hormone replacement therapy in postmenopausal women on urinary C-telopeptide and N-telopeptide of type I collagen, new markers of bone resorption.J Endocrinol Invest. 1998 Mar;21(3):154-9. doi: 10.1007/BF03347294. J Endocrinol Invest. 1998. PMID: 9591210
-
Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease.World J Gastroenterol. 2006 Sep 21;12(35):5680-6. doi: 10.3748/wjg.v12.i35.5680. World J Gastroenterol. 2006. PMID: 17007022 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources